IAVI and Merck, known as MSD outside the United States and Canada, are collaborating to develop an investigational vaccine against SARS-CoV-2 to be used for the prevention of COVID-19. This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis for Merck’s Ebola Zaire virus vaccine, ERVEBO® (Ebola Zaire Vaccine, Live), which was the first rVSV vaccine approved for use in humans. Use of an established vaccine technology could speed development, clinical testing, and approval of the vaccine candidate in the midst of the continuing global public health threat of the COVID-19 pandemic.
The coronavirus vaccine program leverages IAVI’s expertise in rVSV vector technology that it has developed through its rVSV HIV vaccine candidate and its viral hemorrhagic fever vaccine candidates in preclinical development.
IAVI and Merck will work together to advance the development and global clinical evaluation of the SARS-CoV-2 vaccine candidate designed and engineered by IAVI scientists at the Design and Development Lab in Brooklyn, New York, a global leader in viral vector vaccine technology. The vaccine candidate is in preclinical development, and clinical studies are planned to start later in 2020. Merck will lead regulatory filings globally. Both organizations will work together to develop the vaccine and make it accessible and affordable globally, if approved.
The Government of Japan in partnership with the World Bank has announced their intention to commit significant funding to IAVI’s COVID-19 vaccine development program.
In collaboration with Scripps Research and University of California San Diego, researchers at IAVI’s Neutralizing Antibody Center are applying platforms that have been used to discover HIV broadly neutralizing antibodies to discover antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19. They are using those antibodies to identify vulnerable sites on SARS-CoV-2 to improve vaccine design and development and will potentially advance the antibodies for therapy and prevention.
Together with partners in India, Africa, and the U.S., IAVI has been engaging in educational webinar series to provide our stakeholders with timely updates on COVID-19 product development and to help dispell harmful pandemic myths within vulnerable communities. This includes an ongoing multi-part series for health and science journalists hosted by IAVI, the India Alliance, and Nature India. IAVI is also a periodic partner in the PROTOcall webinar series for journalists in India. The series is held each Thursday by the non-profit International Center for Journalists; its project International Journalists’ Network; and PROTO, a social enterprise that is trying to achieve better outcomes in civic media through collaboration and research in India. Watch a recording below or visit our YouTube channel to watch recordings of all previous webinars.
MORE COVID-19 NEWS from iavi
Seventh edition of webinar series tackles community engagement in a time of social distancing.May 26, 2020
New collaboration to leverage complementary expertise and capabilities with rVSV technology to advance novel vaccine candidateApril 23, 2020
Japan's commitment to contribute to the World Bank for COVID-19 vaccine research sets example and will advance global health, IAVI says (in Japanese).April 22, 2020
Japan's Commitment to Contribute to the World Bank for COVID-19 Vaccine Research Sets Example and Will Advance Global Health, IAVI Says
Government of Japan, in partnership with the World Bank, commits funds to COVID-19 vaccine development.March 30, 2020
IAVI's response to the COVID-19 pandemic